Latest Prostate cancer Stories
ATLANTA, Dec. 17, 2012 /PRNewswire/ -- Elekta has received 510(k) clearance for its Clarity® 4D Monitoring software, enabling U.S. medical centers to implement this new way of reducing the uncertainty caused by prostate motion during radiation treatment. Physicians will be able to monitor the motion of the prostate and surrounding tissues and organs - in real-time and with sub-millimeter accuracy - during the delivery of therapeutic radiation beams. The ability to continuously...
Care improving for colorectal and other cancer patients - but still room for improvement TORONTO, Dec. 17, 2012 /CNW/ - A comprehensive report released today by the Canadian Partnership Against Cancer provides a snapshot of how Canada's cancer system is performing in key areas from prevention through to patient experience and outcomes. Produced in collaboration with cancer programs in each province and territory, the 2012 Cancer System Performance Report is intended to inform...
A new study (1) links both cancer growth and metastasis to lack of naturally produced melatonin. Avoiding loss of melatonin due to exposure to light (especially the blue rays in ordinary white light) in the hours before bedtime may reduce risk. Light bulbs that don’t make blue light and eyeglasses that block it are available from Photonic Developments LLC at http://www.LowBlueLights.com. University Heights, OH (PRWEB) December 14, 2012 Metastasis of cancer to distant sites is the thing...
Previously unknown protein function could be a treatment target Scientists at Dana-Farber Cancer Institute have discovered a molecular switch that enables advanced prostate cancers to spread without stimulation by male hormones, which normally are needed to spur the cancer's growth. They say the finding could lead to a new treatment for prostate cancers that are no longer controlled by hormone-blocking drugs. The researchers report in the Dec. 14 issue of Science that the molecular...
NEW YORK, Dec. 14, 2012 /PRNewswire/ -- Despite the volume of prostate cancer tests and treatments, experts and their patients are continually challenged to predict the disease's course and apply the most appropriate treatment. Now, two new diagnostic innovations - the PCA3 urine test and a more targeted prostate biopsy technique - could refine the way doctors diagnose prostate cancer and, subsequently, the way patients elect to treat it. (Photo:...
WAYNE, N.J., Dec. 14, 2012 /PRNewswire/ -- Bayer HealthCare today announced that the company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for radium Ra 223 dichloride (radium-223), an investigational compound for the treatment of castration-resistant prostate cancer (CRPC) patients with bone metastases. "If approved, radium-223 has the potential to play a key role in the treatment of men with CRPC that has metastasized to...
AMES, Iowa, Dec. 13, 2012 /PRNewswire/ -- NewLink Genetics Corporation (Nasdaq: NLNK) today announced that the results of a Phase 1 dose escalation study with its proprietary HyperAcute Prostate Cancer Immunotherapy were published in the Journal of Immunotherapy. The article, entitled "Cellular Immunotherapy Study of Prostate Cancer Patients and Resulting IgG Responses to Peptide Epitopes Predicted From Prostate Tumor-associated Autoantigens," is featured in the current edition of...
Leading the fight against the prostate cancer crisis. BOSTON, Dec. 13, 2012 /PRNewswire-USNewswire/ -- Boston-based AdMeTech Foundation announced jointly with Arthur Murray International that celebrities from ABC's Dancing with the Stars, Maria Menounos (host, EXTRA), Mary Murphy (judge, Fox's So You Think You Can Dance) and actress Florence Henderson will join US Senator John Kerry, Massachusetts Governor Deval Patrick, key legislators and philanthropists in supporting AdMeTech...
Dundas Data Visualization is proud to announce the results of the various Holiday Charity activities they have taken part in over the winter months. Toronto (PRWEB) December 12, 2012 In addition to raising a considerable charitable sum to combat prostate cancer while growing some upper-lip hair on behalf of Movember, the Dundas Dash-staches finished within the Top 2% Worldwide! Adding to the holiday cheer, Dundas also hosted their annual Toy Drive in December which saw the company donate...
RARITAN, N.J., Dec. 12, 2012 /PRNewswire/ -- Janssen Research & Development, LLC announced today that results from analyses of COU-AA-302, a Phase 3, randomized, placebo-controlled study of ZYTIGA(® )(abiraterone acetate) plus prednisone for the treatment of metastatic castration-resistant prostate cancer (mCRPC) prior to chemotherapy, have been published online in The New England Journal of Medicine. This study was the basis of Monday's U.S. Food and Drug Administration (FDA)...
